About

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life…

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life Sciences teams.

Latest Post

On January 18, 2024, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued its first untitled letter of the new year to Novartis Pharmaceuticals Corporation (Novartis) regarding a promotional, direct-to-consumer broadcast advertisement (TV Ad) for KISQALI® (ribociclib) tablets, for oral use, indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

Continue Reading FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®

About

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life…

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life Sciences teams.

Subscribe: Subscribe via RSS